Company news

UroGen Pharma Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

February 2, 2022

UroGen Pharma to Present at Upcoming Conferences

January 4, 2022

First Patient Dosed in UroGen Pharma’s Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)

December 20, 2021

UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

November 14, 2021

UroGen Pharma Announces Upcoming 2021 Conferences

November 10, 2021

UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event

November 9, 2021

UroGen Pharma to Host Virtual Spotlight Event on November 10, 2021

October 31, 2021

The Journal of Urology Publishes Results of UroGen Pharma’s Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)

October 4, 2021

UroGen Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference

September 22, 2021

UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual Meeting

September 12, 2021

UroGen Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 9, 2021

UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

August 3, 2021

UroGen Pharma to Report Second Quarter 2021 Financial Results on Wednesday, August 4, 2021

July 27, 2021

UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto® in Israel

July 27, 2021

UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021

July 13, 2021

UroGen Pharma to Present at Ladenburg Thalmann Healthcare Conference

July 6, 2021

UroGen Pharma Announces June 2021 Conference Schedule

May 24, 2021

UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments

May 12, 2021

UroGen Pharma to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021

May 5, 2021

UroGen Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments

March 17, 2021

UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments

March 17, 2021

UroGen Pharma Announces Sponsored Research Agreement with the Johns Hopkins University School of Medicine to Expand Immuno-Oncology Pipeline

March 14, 2021

UroGen Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 18, 2021

March 10, 2021

UroGen Pharma Announces March 2021 Conference Schedule

February 22, 2021

UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer

January 12, 2021

UroGen Pharma to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference

January 5, 2021

UroGen Pharma Announces Podium Presentation of Final Jelmyto® Data From Pivotal OLYMPUS Trial at the Annual Meeting of the Society of Urologic Oncology

December 2, 2020

Complete and Durable Responses Observed in OPTIMA II Phase 2b Final Results for UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer

November 16, 2020

Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for UroGen’s Jelmyto® Effective January 1, 2021

November 10, 2020

UroGen Pharma Announces November 2020 Conference Schedule

November 9, 2020

UroGen Pharma Reports Third Quarter 2020 Financial Results and Recent Corporate Developments

November 8, 2020

UroGen Pharma to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020

November 1, 2020

UroGen Pharma Announces September 2020 Conference Schedule

September 9, 2020

UroGen Pharma Expands Executive Team to Accelerate Platform Innovation and Drive Commercial Growth

September 8, 2020

UroGen Pharma Announces Update on the Phase 2 Trial of an RTGel™ Hydrogel Formulation in Combination with BOTOX® (onabotulinumtoxinA) Intravesical Instillation for Overactive Bladder and Urinary Incontinence

August 26, 2020

UroGen Pharma Reports Second Quarter 2020 Financial Results and Recent Corporate Developments

August 9, 2020

UroGen Pharma to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020

August 2, 2020

UroGen Pharma to Present at Jefferies Virtual Healthcare Conference

May 31, 2020

UroGen Pharma Announces First Presentation of Data from Phase 2b Study of UGN-102 in Patients with Difficult to Treat Type of Bladder Cancer

May 14, 2020

UroGen Announces Positive Data from Pivotal OLYMPUS Trial Evaluating Jelmyto™ in Patients with Low-Grade Upper Tract Urothelial Cancer

May 14, 2020

UroGen Pharma Reports First Quarter 2020 Financial Results and Recent Corporate Developments

May 6, 2020

UroGen Pharma to Report First Quarter 2020 Financial Results On Thursday, May 7, 2020

April 30, 2020

The Lancet Oncology Publishes Details of UroGen Pharma’s Pivotal OLYMPUS Trial

April 29, 2020

UroGen Pharma Receives U.S. FDA Expedited Approval for Jelmyto™, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer

April 14, 2020

UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer

April 2, 2020

UroGen Pharma Promotes Key Personnel Focused on Commercial Operations and Expanded Clinical Development

March 22, 2020

UroGen Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments

March 1, 2020

UroGen Pharma Announces March 2020 Investor Conference Schedule

February 24, 2020

UroGen Pharma Announces FDA Filing Acceptance and Priority Review of U.S. New Drug Application (NDA) for UGN-101

December 18, 2019

UroGen Pharma Reports Third Quarter 2019 Financial Results and Recent Corporate Developments

November 11, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 10 decks. Every deck is listed under its year.